Article
Oncology
Ahmed El-Hemaly, Hala Taha, Amal Refaat, Fatima Adel, Mohamed Elbeltagy, Omar Arafah
Summary: This study found that age significantly affected the efficacy of salvage therapy for low-grade glioma, while three different salvage regimens were equally effective in terms of radiological response and visual outcome.
Article
Pharmacology & Pharmacy
Mourad Hamimed, Florence Gattacceca, Nicolas Andre, Emmanuelle Tresch-Bruneel, Alicia Probst, Pascal Chastagner, Anne Pagnier, Emilie De Carli, Natacha Entz-Werle, Jacques Grill, Isabelle Aerts, Didier Frappaz, Anne-Isabelle Bertozzi-Salamon, Caroline Solas, Pierre Leblond
Summary: The PK profile of orally administered vinorelbine was assessed in children with recurrent/progressive low-grade glioma. Higher doses may be necessary for children with LGG, and body surface area has a significant impact on vinorelbine systemic exposure. These findings will contribute to further research on vinorelbine concentration-response relationships in pediatric patients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Oncology
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, Shengjie Wu, Azra H. Ligon, Neal Lindeman, Olivia Campagne, Anu Banerjee, Sridharan Gururangan, Lindsay B. Kilburn, Stewart Goldman, Ibrahim Qaddoumi, Patricia Baxter, Gilbert Vezina, Corey Bregman, Zoltan Patay, Jeremy Y. Jones, Clinton F. Stewart, Michael J. Fisher, Laurence Austin Doyle, Malcolm Smith, Ira J. Dunkel, Maryam Fouladi
Summary: This study presented the results of treating children with recurrent/progressive OPHGs using selumetinib in a PBTC phase II trial. The treatment resulted in partial responses in 24% of patients, stable disease in 56%, and disease progression in 20%, with a median number of 26 treatment courses. The two-year PFS was 78%, and evaluation of visual acuity showed improvement and stability in a portion of patients.
Article
Oncology
Marcos Devanir da Costa, Rodrigo Akira Watanabe, Carolina Torres Soares, Natalia Dassi, Patricia Alessandra Dastoli, Jardel Mendonca Nicacio, Andrea Maria Cappellano, Nasjla Saba Silva, Sergio Cavalheiro
Summary: Optic pathway gliomas can result in elevated cerebrospinal fluid protein concentrations. Bevacizumab treatment can decrease protein levels and facilitate successful shunt placement.
PEDIATRIC BLOOD & CANCER
(2022)
Review
Oncology
Pushan Dasgupta, Veerakumar Balasubramanyian, John F. F. de Groot, Nazanin K. K. Majd
Summary: Preclinical models are crucial for understanding glioma biology and developing therapeutics. However, the development of ideal models is challenging due to various factors, such as genetic background, tumor heterogeneity, intact blood-brain barrier, and the tumor microenvironment. In this review, we discuss in vitro and in vivo models of glioma and the challenges involved in developing optimal models.
Review
Cell Biology
Simone Dal Bello, Deborah Martinuzzi, Yan Tereshko, Daniele Veritti, Valentina Sarao, Gian Luigi Gigli, Paolo Lanzetta, Mariarosaria Valente
Summary: This review discusses the established standards of care for optic pathway gliomas (OPGs), and highlights emerging therapeutic strategies and potential alternative therapies for OPG treatment. It also addresses the challenges of restoring visual function in cases of optic nerve damage and explores ongoing research in this area, particularly involving stem cells.
Article
Oncology
Carlien A. M. Bennebroek, Judith van Zwol, Giorgio L. Porro, Rianne Oostenbrink, Anne T. M. Dittrich, Annabel L. W. Groot, Jan W. Pott, Etienne J. M. Janssen, Noel J. Bauer, Maria M. van Genderen, Peerooz Saeed, Maarten H. Lequin, Pim de Graaf, Antoinette Y. N. Schouten-van Meeteren
Summary: The study found that treatment with bevacizumab in pediatric patients with optic pathway glioma can temporarily stabilize the majority of patients and improve visual acuity to some extent, but most patients still experience disease progression over time.
Article
Oncology
Pierluigi Calo, Nicolas Pianton, Alexandre Basle, Alexandre Vasiljevic, Marc Barritault, Pierre Aurelien Beuriat, Cecile Faure-Conter, Pierre Leblond
Summary: Currently, there is no clear consensus on the best treatment for children with optic pathway gliomas (OPG). Different chemotherapy regimens have been proposed, but none have proven superiority in terms of progression-free survival (PFS). Recent publications have suggested that the combination of bevacizumab and irinotecan may be effective, although irinotecan has shown digestive side effects. This retrospective study evaluated the efficacy of bevacizumab used as a single agent in children with OPG, and found promising results in terms of tumor response rate and disease control.
Article
Pharmacology & Pharmacy
Adenike O. Adekeye, David Needham, Ruman Rahman
Summary: This study determined LDL receptor (LDLR) expression in high grade gliomas (HGGs) using immunohistochemistry and confirmed its potential as a therapeutic target. The study also analyzed LDLR expression levels in three cell line models, confirming their suitability for testing LDLR-targeted nanoparticle uptake, retention, and cytotoxicity.
Review
Oncology
Marco Gallus, Darwin Kwok, Senthilnath Lakshmanachetty, Akane Yamamichi, Hideho Okada
Summary: IDH-mutant low-grade gliomas (LGG) are slow-growing glial cell-derived tumors of the central nervous system (CNS) that predominantly manifest in young adults and often show malignant transformation. Despite therapeutic advances in other areas, immunotherapies remain ineffective in treating LGG patients. This review summarizes relevant research findings and discusses challenges and lessons learned from clinical trials, as well as future perspectives on improving immunotherapy for IDH-mutant LGG.
Article
Oncology
Danielle Golub, Daniel G. Lynch, Peter C. Pan, Benjamin Liechty, Cheyanne Slocum, Tejus Bale, David J. Pisapia, Rupa Juthani
Summary: Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a rare tumor that can mimic high-grade glioma in histologic and molecular features. This study describes a case of indolent neuroepithelial neoplasm in an adult female patient and compares it with adult glioma patients harboring FGFR3-TACC3 fusion gene. The presence of FGFR3-TACC3 fusion gene and other high-grade features should raise concern for a more malignant precursor lesion in the diagnosis of PLNTY.
FRONTIERS IN ONCOLOGY
(2023)
Article
Clinical Neurology
Andrew J. Gogos, Jacob S. Young, Matheus P. Pereira, Ramin A. Morshed, Matthew B. Potts, Shawn L. Hervey-Jumper, Mitchel S. Berger
Summary: The study reported the surgical treatment experience for incidental LGG, which were smaller and showed improved overall survival compared to symptomatic tumors.
JOURNAL OF NEUROSURGERY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kareem Kudus, Matthias W. Wagner, Khashayar Namdar, Liana Nobre, Eric Bouffet, Uri Tabori, Cynthia Hawkins, Kristen W. Yeom, Birgit B. Ertl-Wagner, Farzad Khalvati
Summary: We established a nomogram to predict BRAF status non-invasively in pediatric low-grade glioma (pLGG) patients, using clinical and radiomic factors. Additionally, we assessed an advanced thresholding method to provide high-confidence predictions. Radiomic features were found to provide additional predictive information beyond tumor location.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
Meng Zhang, Dan Wang, Lan Su, Jingjiao Ma, Sizhen Wang, Meng Cui, Shunming Hong, Bing Guan, Xiaodong Ma
Summary: The study thoroughly characterized the activity of the Wnt/PCP regulation pathway in low-grade glioma (LGG) patients, revealing three subgroups with significant survival differences and distinct genomic characteristics. Each subgroup had different genetic features, with C1 enriched in CIC truncating mutations and 1p19q codel, C2 characterized by TP53 and ATRX inactivating mutations but lacking TERT promoter mutations, and C3 showing the worst survival outcome and elevated malignancy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Alexander N. Hanania, Arnold C. Paulino, Ethan B. Ludmir, Veeral S. Shah, Jack M. Su, Susan L. McGovern, Patricia A. Baxter, Mary Frances McAleer, David R. Grosshans, M. Fatih Okcu, Murali M. Chintagumpala
Summary: This study longitudinally assessed the visual acuity among children treated at Texas Children's Cancer Center in Houston over the past two decades, finding that early radiation therapy had superior blindness-free survival for pediatric patients with sporadic optic pathway/hypothalamic gliomas.